Course length of 30 metres versus 10 metres has a significant influence on six-minute walk distance in patients with COPD: an experimental crossover study  by Beekman, Emmylou et al.
Journal of Physiotherapy 2013  Vol. 59  –  © Australian Physiotherapy Association 2013 169
Beekman et al: Course length for 6-min walk test in COPD
Introduction
The six-minute walk test (6MWT) is recommended as a 
reliable, valid, and responsive test to measure functional 
exercise capacity in adults with chronic obstructive 
pulmonary disease (COPD) by the American Thoracic 
Society (ATS 2002) and others (Enright 2003, Rasekaba et 
al 2009). Health professionals’ preference for the 6MWT 
may be due to its close relation to activities in daily life, its 
simplicity, and its broad applicability in frail elderly people 
or patients who cannot be tested with standard tests like 
a 12 minute walk test, shuttle walk test, maximal cycle 
ergometer, or treadmill tests. The 6MWT also takes less 
time and costs less to perform than more extensive tests 
(ATS 2002, Brown and Wise 2007). It is most suitable 
to evaluate the effects of medical interventions in people 
with moderate to severe heart or lung disease (ATS 2002). 
Furthermore, the 6MWT is used as a diagnostic assessment 
of functional status to justify treatment plans in primary 
COPD care and as a predictor of morbidity and mortality 
(ATS 2002). Although forced expiratory volume in one 
second (FEV1) remains the most important physiological 
indicator of the severity of airﬂow obstruction in people with 
COPD, its predictive value for mortality is weak when FEV1 
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6-minute walk test
is higher than 50% of the age-predicted value (Pinto-Plata 
et al 2004). On the other hand, achieving a 6MWT distance 
(6MWD) of less than 82% of the predicted value can be 
considered abnormal (Troosters et al 1999) and a distance 
of less than 350 m or a fall of 30 m in 12 months is strongly 
associated with increased mortality in people with COPD 
8IBUJTBMSFBEZLOPXOPOUIJTUPQJD The 6-minute 
walk test is widely used and well validated in people 
with chronic obstructive pulmonary disease (COPD), 
in whom it predicts morbidity and mortality. Major 
guidelines state that the test should be conducted on 
a 30 m straight course but, due to space limitations, 
many physiotherapists conduct the test on a 10 m 
course.
8IBUUIJTTUVEZBEET In comparison to a 30 m 
course, use of a 10 m course signiﬁcantly shortens the 
distance that people with COPD achieve on a 
6-minute walk test. Normative equations and 
prognostic abilities derived from 6-minute walk tests 
conducted on a 30 m course cannot be assumed to 
be applicable to test results obtained on a 10 m course.
. Open access under CC BY-NC-ND license.
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Table 1. Overview of published studies with reference equations for 6MWD involving healthy individualsa.
Study n Trackb 
(m)
Participants Reference equations r2
Tsang 2005 548 15 Chinese 
21–70 yr
Reference values (age and gender speciﬁc) available in article,
no equations
Gibbons et al 2001 79 20 Canadian 
20–80 yr
ƃ 6MWDm = 868.8 – (2.99*ageyears)
Ƃ 6MWDm = 868.8 – (2.99*ageyears) – 74.7
0.41
0.41
Chetta et al 2006 102 30 Caucasian 
20–50 yr
ƃ 6MWDm = 518.853 + (1.25*heightcm) – (2.816*ageyears)
Ƃ 6MWDm = 518.853 + (1.25*heightcm) – (2.816*ageyears) – 39.07
0.42
0.42
Masmoudi et al 2008 155 30 Tunisian 
40–80 yr
ƃ 6MWDm = 299.8 – (4.34*ageyears) + (342.6*heightm) – (1.46*weightkg) + 62.5, LLN = calculated value – 124.5 m
Ƃ6MWDm = 299.8 – (4.34*ageyears) + (342.6*heightm) – (1.46*weightkg), LLN = calculated value – 124.5 m
0.60
0.60
Alameri et al 2009 298 30 Arab 
18–50 yr
ƃ6MWDm = (2.81*heightcm) + (0.79*ageyears) – 28.5
Ƃ 6MWDm = (2.81*heightcm) + (0.79*ageyears) – 28.5
0.25
0.25
Iwama et al 2009 134 30 Brazilian 
> 13 yr
ƃ6MWDm = 622.461 – (1.846*ageyears) + 61.503, SEE = 70.992 m
Ƃ 6MWDm = 622.461 – (1.846*ageyears), SEE = 70.992 m
0.30
0.30
Osses et al 2010 175 30 Chilean 
20–80 yr
ƃ 6MWDm = 530 – (3.31* ageyears) + (2.36* heightcm) – (1.49* weightkg), SEE = 58 m
Ƃ 6MWDm = 457 – (3.46* ageyears) + (2.61* heightcm) – (1.57* weightkg), SEE = 53 m
0.55
0.63
4PBSFT1FSFJSB 132 30 Brazilian 
20–80 yr
ƃ 6MWDm = 390 + (2.14*heightcm) – (2.37*ageyears) – (2.34*BMI), 5th percentile = 121 m
Ƃ 6MWDm = 683 + (0.91*heightcm) – (3.94*ageyears) – (3.57*BMI), 5th percentile = 97 m
0.33
0.71
Casanova et al 2011 444 30 Caucasian 
American 
40–80 yr
ƃ 6MWDm = 361 – (4* ageyears) + (2* heightcm
	)3NBY)3NBYQSFE
o	XFJHIUkg)
Ƃ 6MWDm = 361 – (4* ageyears) + (2* heightcm
	)3NBY)3NBYQSFE
o	XFJHIUkg) – 30
0.38 
0.38
Hill et al 2011 77 30 Canadian 
45–85 yr
ƃ 6MWDm = 970.7 + (-5.5*ageyears) + 56.3
Ƃ 6MWDm = 970.7 + (-5.5* ageyears)
0.49
0.49
&OSJHIU4IFSSJMM 290 30.5 North 
American 
40–80 yr
ƃ 6MWDm = (7.57*heightcm) – (5.02*ageyears) – (1.76*weightkg) – 309, LLN = calculated value – 153 m
Ƃ 6MWDm = (2.11*heightcm) – (5.78*ageyears) – (2.29*weightkg) + 667, LLN = calculated value – 139 m
0.42
0.38
Enright et al 2003 2281 30.5 North 
American 
* 68 yr
ƃ 6MWDm = 493 + (2.2*heightcm) – (0.93*weightpound) – (5.3*ageyears) + 17
Ƃ 6MWDm = 493 + (2.2*heightcm) – (0.93*weightpound) – (5.3*ageyears)
0.20
0.20
Ben Saad et al 2009 229 40 North 
African 
* 40 yr
ƃ 6MWDm = 720.50 – (5.14*ageyears) – (2.23*weightkg) + (271.98*heightm), LLN = calculated value – 89 m
Ƃ 6MWDm = 720.50 – (5.14*ageyears) – (2.23*weightkg) + (271.98*heightm) – 160, LLN = calculated value – 89 m
0.77
0.77
Poh et al 2006 35 45 Chinese 
45–85 yr
ƃ 6MWDm = (5.50*HRmax%pred) + (6.94*heightcm) – (4.49*ageyears) –  (3.51*weightkg) – 473.27
Ƃ 6MWDm = (5.50*HRmax%pred) + (6.94*heightcm) – (4.49*ageyears) –  (3.51*weightkg) – 473.27
0.78 
0.78
Camarri et al 2006 70 45 Caucasian 
Australian 
55–75 yr
ƃ 6MWDm = 64.69 + (3.12*heightcm) + (23.29*FEV1, litres)
Ƃ 6MWDm = 64.69 + (3.12*heightcm) + (23.29*FEV1, litres)
0.34
0.34
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(Polkey et al 2012, Rasekaba et al 2009). As a component of 
the BODE index (BMI, airﬂow Obstruction, Dyspnoea and 
Exercise), but also as an independent measure, the 6MWD 
predicts COPD-related mortality better than FEV1 alone 
(Pinto-Plata et al 2004).
The American Thoracic Society guidelines (ATS 2002) 
state that the walking course for the 6MWT must be 30 m 
in a straight line. Normative values have been established 
for this distance and other distances, mainly exceeding 30 
m. An overview of published reference equations for the 
6MWT on various course lengths is shown in Table 1.
In physiotherapy practices in a primary care setting, a 30 
m straight or circular course is often not available, while 
continuous (oval) courses increase the distance achieved 
(Sciurba et al 2003). Space limitations frequently force 
clinicians and researchers to administer the 6MWT on a 
10 m course. Being aware of the space limitation, a COPD 
guideline for physiotherapists advocates performance of the 
standardised 6MWT on a course of at least 10 m (Gosselink 
et al 2008).
Studies on whether course length impacts the performance 
of patients with COPD are inconclusive. In a cross-
sectional study, Sciurba and colleagues (2003) compared 
6MWDs of different subjects in different centres and 
reported that course lengths ranging from 17 m to 55 m 
had no signiﬁcant effect on walk distance of 761 patients 
with severe emphysema. However, Enright and colleagues 
(2003) suggested in a narrative review that the greater 
number of turns with a shorter course length is one of the 
factors associated with achieving a shorter distance. So 
far, only one study has published the effects of walkway 
length comparing 10 m and 30 m in healthy adults (Ng et 
al 2013). Similarly, only one study has examined this in 
patients with stroke, who are limited in their walking speed 
due to abnormal gait and reduced walking endurance (Ng 
et al 2011). Although these studies concluded that different 
course lengths have a signiﬁcant effect on the 6MWD, the 
question remains whether the same effect occurs in people 
with COPD, who are limited in their walking speed due 
to dyspnoea and/or peripheral muscle fatigue. This may 
invalidate the use of reference equations with results from 
6MWTs conducted on different course lengths than the 
one used to generate the reference equations. No study has 
described the difference in 6MWD on 10 m versus 30 m 
courses in patients with COPD. Therefore, the research 
questions of the present study were:
1. Do patients with chronic obstructive pulmonary 
disease (COPD) achieve a different distance on a 
6MWT conducted on a 10 m course versus on a 30 
m course?
2. When assessing the distance on a 6MWT conducted 
on a 10 m course, is it valid to use existing reference 
equations that were generated on longer courses?
Method
Design
A double-crossover design was used to measure the 6MWD 
on different course lengths. Patients were instructed to attend 
the rehabilitation centre twice, with seven days between the 
visits. This was done to correct for the learning effect that 
has been reported in patients with COPD (Hernandes et al 
2011) and because performance usually reaches a plateau 
Beekman et al: Course length for 6-min walk test in COPD
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Research
after two tests done within a week (ATS 2002). On the ﬁrst 
day, patients walked up and down both a 10 m course for 
six minutes and a 30 m course for six minutes, separated 
by a rest period of at least 30 minutes. The order in which 
the different course lengths were tested was randomised. 
One week later the participants repeated the two tests at the 
same time of the day but in the reverse order.
Participants
Participants were recruited by the researchers (EB and 
IM) at a primary care physiotherapy practice specialised 
in COPD rehabilitation in the south of the Netherlands. 
Prior to the 6MWT people attending the physiotherapy 
practice were screened by the researcher (EB). They were 
considered eligible to participate if they had a conﬁrmed 
diagnosis of COPD (by a pulmonologist or general 
practitioner) according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD 2010); were clinically 
stable (no signs of pulmonary exacerbation); were able 
to execute the 6MWT; and were able to understand the 
protocol instructions. All participants completed a health 
status questionnaire to record comorbidities and the results 
of their most recent lung function test.
On the day of testing all patients conﬁrmed taking their 
prescribed medication (bronchodilators and medication 
for co-morbidities). They were required to abstain from 
short-acting bronchodilators for at least two hours before 
spirometry and the 6MWTs (Brown and Wise 2007). 
Height, body weight, age, sex, and smoking habits were 
recorded. The intensity and frequency of physical activity 
in daily life was scored using the Physical Activity 
Questionnaire, with 0 to 3 being insufﬁciently active and 
4 or above being sufﬁciently active (Gosselink et al 2008). 
Heart rate, resting diastolic and systolic blood pressure were 
measured twice on both arms with a digital blood pressure 
monitora. Relative contra-indications for the 6MWT were 
a resting heart rate over 120 beats/min, systolic blood 
pressure above 180 mmHg, and diastolic blood pressure 
above 100 mmHg. Spirometry was performed by one 
researcher (EB) using an electronic spirometerb to measure 
forced vital capacity (FVC), FEV1, and forced expiratory 
ratio (FEV1/FVC) according to the GOLD and ATS/ERS 
guidelines for spirometry (GOLD 2010). The results in 
litres were converted to a percentage of the predicted values 
reported by Quanjer and colleagues (1993). The severity of 
COPD was recorded by stage, deﬁned by the GOLD criteria 
(GOLD 2010).
Intervention
Each patient performed the 6MWT four times. All 6MWTs 
were performed in accordance with the ATS guidelines 
(2002), except for the course length, which was adjusted 
as described above. Participants were asked to wear 
comfortable clothes and shoes and make use of their usual 
walking aids (eg, walking stick or rollator) and oxygen 
supply (if applicable). All tests were performed between 
8:00 am and 8:00 pm in a quiet indoor hallway with a ﬂat 
straight ﬂoor with marks at one metre intervals. Two trafﬁc 
cones marked the turning points in the hallway. Participants 
were asked to walk at their own pace, while attempting to 
cover as much ground as possible within the allotted six 
minutes (ATS 2002). Participants were allowed to turn 
in whichever direction they preferred because research 
shows that turning direction seems to have no signiﬁcant 
inﬂuence on the distance covered (Ng et al 2011, Ng et al 
2013). Every minute, researchers encouraged subjects to 
continue walking and informed them of the time elapsed, 
using standardised phrases (ATS 2002). Participants were 
allowed to stop and rest during the test, but were instructed 
to continue the test as soon as possible.
Outcome measures
Dyspnoea and fatigue were rated by the participant at rest 
(after sitting for at least 15 minutes, preceding the 6MWT) 
and directly after exercise, using a laminated modiﬁed 
Borg scale ranging from 0 (nothing at all) to 10 (very, very 
severe). At the same times, heart rate and oxygen saturation 
(SpO2) were measured using a ﬁnger pulse oximeterc. All 
tests were supervised by the same researcher (EB). For each 
participant, the 6MWD was deﬁned as the greater distance 
achieved on the two tests (ATS 2002). The better test was 
identiﬁed for both the 10 m course and the 30 m course.
Data analysis
The number of participants for the study was based on an 
estimated mean standard deviation of 103 metre (Puhan 
et al 2008, Sciurba et al 2003), an estimated correlation 
coefﬁcient between 6MWD on a 30 m course versus on a 
10 m course of r = 0.7, and a predicted mean difference 
of 35 m, reasoning that a difference in 6MWD larger than 
the most conservative minimal important difference will 
justify new reference equations for a 10 m course (Puhan 
et al 2008). Consequentially, the number of patients with 
COPD needed (with Ð = 0.05 and 1-Ð = 0.80) was 45 
subjects. Data were presented as means (SD) for normally 
distributed variables and medians (5th to 95th percentile) 
for those with non-normal distribution. Data of all subjects 
(n = 45) were checked for missing values, distribution (with 
the Kolmogorov-Smirnov test of normality), and outliers. 
Pearson correlation coefﬁcients, Intraclass Correlation 
Coefﬁcients (ICCconsistency), Standard Errors of 
Measurement (SEMconsistency) and Bland-Altman plots 
were produced for the two 6MWTs over the 10 m course, 
for the better 6MWD over the 10 m and 30 m course, and 
for the deviation between measured and predicted 6MWD. 
The difference between 6MWD over the 10 m and 30 m 
course was analysed using a one-tailed t-test, expecting a 
one-sided effect in favour of the longer course length based 
on the existing literature (Enright 2003, Ng et al 2011, Ng 
et al 2013). Deviations of measured 6MWD compared to 
predicted distances (%pred), based on existing reference 
equations in similar-aged Caucasian populations and 
with similar submaximal effort (ie, comparable to study 
population) were used to understand the impact of course 
length on the use of reference equations (Gibbons et al 2001, 
Hill et al 2011, Jenkins et al 2009, Troosters et al 1999). The 
range of differences in %pred values for the 6MWT over a 10 
m course were given as well as the average %pred 6MWD 
to compare both course lengths. At a minimal statistical 
power of 80%, p values below 0.05 were considered to be 
signiﬁcant.
Results
Flow of participants
Forty-ﬁve patients with COPD, aged 47 to 87 years, were 
recruited. All participants were familiar with the 6MWT 
at the time of recruitment. Three patients dropped out 
of the second 6MWT due to medical reasons (n = 2, ﬂu 
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and hospitalisation) or private reason (n = 1, holiday). The 
ﬁrst 6MWD in these three patients was used as their best 
test, based on the remaining 42 participants having a non-
signiﬁcant learning effect over both courses of 0% (p > 0.1) 
for the 10 m course and 2% (p > 0.1) for 30 m course, high 
correlations between the ﬁrst and second tests (r = 0.98, p 
< 0.001 for the 10 m course and r = 0.92, p < 0.001 for the 
30 m course), and no substantial offset (ie, 95% and 90%, 
respectively, of the difference scores were within the limits 
of agreement in Bland-Altman plots).
Patient characteristics are summarised in Tables 2 and 3. 
All variables were normally distributed, apart from physical 
activity score, change in heart rate, SpO2, Borg dyspnoea 
and Borg fatigue, which were expected to be skewed, since 
this study population consists of older adults with COPD, 
disabled in their activity level.
.8%PWFSNWFSTVTNDPVSTFMFOHUI
The 6MWDs on the 10 m and 30 m courses were both 
normally distributed and there were no signiﬁcant outliers. 
All participants achieved a shorter 6MWD on the 10 
m course than on the 30 m course. The mean difference 
between the better 6MWD on the 10 m versus 30 m course 
was 49.5 m (SD 33.6; range 9–143; one-tailed t = –9.9, p < 
0.001). There was a high Pearson correlation between the 
better 6MWD on the 10 m and 30 m courses (r = 0.96, p < 
0.01). Furthermore, a high ICCconsistency (0.86, 95% CI 
0.76 to 0.92) was revealed between 6MWD on the 10 m and 
30 m courses, without substantial offset (SEMconsistency 
= 41.14 and 93% of the difference scores within the limits 
of agreement: –16.32 m to 115.30 m). Figure 1 shows the 
systematic lower performance on the 10 m course compared 
to the 30 m course, regardless of test performance.
Impact of course length on use of reference 
equations
Established values to predict the 6MWD were compared 
with the measured 6MWDs of the participants. Every 
reference equation that included Caucasian subjects 
overestimated the measured 6MWDs of the participants, 
which was to be expected because prediction models are 
based on healthy subjects. The predicted values compared 
to the achieved 6MWDs on the 10 m course showed an 
overestimation ranging from 30% to 33%. However, the 
predicted 6MWD was based on four prediction models 
that are all established with walking courses exceeding 10 
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Table 2. Characteristics of the participants.
Characteristic Participants 
(n = 45)
Sex, n male (%) 26 (58)
Age (yr), mean (SD) 67 (9)
Height (cm), mean (SD) 169 (8)
Weight (kg), mean (SD) 81 (17)
BMI (kg/m2), mean (SD) 28.4 (5.1)
FVC (L), mean (SD) 3.03 (1.03)
 (%pred), mean (SD) 92 (21)
FEV1 (L), mean (SD) 1.49 (0.54)
 (%pred), mean (SD) 56 (19)
FEV1'7$(%), mean (SD) 49 (15)
GOLD Stage, n (%)
 I 6 (13)
 II 21 (47)
 III 12 (27)
 IV 6 (13)
Smoking (pack-yr), mean (SD) 33 (26)
Physical activity level (0–8)
 mean (SD) 3.4 (2.3)
 median (5th to 95th percentile) 4.0 (0.0 to 8.0)
Sufﬁcient physical activity, n (%) 24 (53)
Systolic blood pressure (mmHg), mean (SD) 134 (21)
Diastolic blood pressure (mmHg), mean (SD) 76 (12)
BMI = body mass index, FVC = forced vital capacity, FEV1 = 
forced expiratory volume in one second, GOLD = Global 
obstructive lung disease. GOLD stages: I = mild COPD, FEV1'7$
< 0.7 and FEV1 * 80% of predicted; II = moderate COPD, FEV1
FVC < 0.7 and 50% ) FEV1 < 80% of predicted; III = severe COPD, 
FEV1'7$BOE) FEV1 < 50% of predicted;  
IV = very severe COPD, FEV1'7$BOE'&71 < 30% of 
predicted or FEV1 < 50% of predicted plus chronic respiratory 
failure.
5BCMF Mean (SD) and median (5th to 95th percentile) cardiorespiratory variables at baseline and changes during 
the 6MWT on the 10 m and 30 m courses.
Characteristic Baselinea Change during 6MWTb
10 m course 30 m course
)FBSUSBUF	CFBUTNJO
 82 (14) 25 (16) 25 (17)
83 (58 to 107) 20 (3 to 55) 20 (5 to 64)
SpO2 (%) 95 (2) –6 (6) –6 (5)
96 (90 to 98) –5 (–17 to 1) –5 (–17 to 1)
Borg dyspnoea score (0–10) 2.4 (1.7) 2.4 (1.8) 2.2 (1.8)
2.5 (0.2 to 5.5) 2.0 (0.0 to 6.0) 2.0 (0.2 to 6.4)
Borg fatigue score (0–10) 1.8 (1.8) 1.7 (1.5) 1.6 (1.4)
1.8 (0.0 to 5.7) 1.5 (0.0 to 4.0) 1.5 (0.0 to 4.0)
aBaseline data for each participant was taken as the mean of the values before all four tests, bChange data for each participant 
was taken from the test in which the greater distance was covered. SpO2 = transcutaneous oxygen saturation
metres: Gibbons et al (2001) used a 20 m course, Hill et 
al (2011) used 30 m, Jenkins et al (2009) used 45 m, and 
Troosters et al (1999) used 50 m. Therefore all participants 
showed a higher average %pred 6MWD on the 30 m course 
than on the 10 m course (mean difference = 8%, p < 0.001), 
with no substantial offset in the variation in the %pred 
6MWD over the range of values (ICCconsistency = 0.81, 
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95% CI 0.69 to 0.89; SEMconsistency = 6.56 and 93% of 
the difference scores within the limits of agreement: –2.89 
to 18.67 %pred), as presented in Figure 2.
On average, patients walked 1.9 m less in the second test on 
the 10 m course compared with the ﬁrst (p > 0.1) and 9.5 m 
more in the second test on the 30 m course compared with 
the ﬁrst (p > 0.1). Regarding the test-retest reliability for the 
6MWD on the 10 m course an ICCconsistency of 0.98 was 
found (95% CI 0.96 to 0.99 and 95% of the difference scores 
within the limits of agreement: –42.33 m to 41.56 m).
Discussion
The results of this study are of considerable importance in 
physiotherapy settings in which the 6MWT is conducted. 
Course length substantially inﬂuences the performance of 
patients with COPD in a 6MWT, and the results of the test 
conducted on a 10 m course versus a course of 30 metres 
or longer are not interchangeable. Consequently, using 
existing reference equations to established %pred values 
for the 6MWT causes an overestimation of the functional 
capacity of a COPD patient.
The shorter 6MWD achieved on a 10 m course might 
be explained by the increased number of turns that are 
involved in a shorter walking course (Enright 2003, Ng et 
al 2011, Ng et al 2013). Moreover, Najaﬁ and colleagues 
(2009) showed that older people may choose a higher gait 
speed strategy over a longer walk distance (> 20 m), but 
a slower gait speed strategy over a shorter walk distance 
(< 10 m). Finally, patient-speciﬁc altered gait mechanisms 
(eg, limping, shufﬂing, shorter step length, and slower walk 
speed) may contribute to the difference in 6MWDs over the 
two course lengths (Pepera et al 2012, Yentes et al 2011). Our 
ﬁndings contrasted with those of Sciurba and colleagues 
(2003) who found no statistically signiﬁcant effect of course 
length on 6MWD. However, this study compared different 
course lengths between different centres retrospectively. 
The order of the tests was not randomised (ie, each subject 
was measured on only one course length), only people with 
severe emphysema were included, and the test courses were 
all longer than 17 m (Sciurba et al 2003). The impact of 
the much shorter 10 m course might be the reason for the 
statistical signiﬁcance of the difference. Not only is the 
difference of 49.5 m statistically signiﬁcant, this value is 
also large enough to be of practical relevance. When the 
difference exceeds the minimum clinically important 
differences (MCID), concerns are warranted. Recent 
reported MCIDs for the 6MWD in patients with COPD are 
35 m (95% CI 30 to 42) by Puhan and colleagues (2008) 
and 25 m (95% CI 20 to 61) by Holland and colleagues 
(2010), both on a 30 m course. Our study shows that the 
average difference in walk distance, singly depending on 
the length of the test course, exceeds the MCID (80% of the 
individual cases, as presented in Figure 1). The difference 
in the distance achieved between a 10 m and 30 m course of 
49.5 m allows for the assumption that using a 50 m course 
compared to a 10 m course would increase this difference 
even further. A 6MWD obtained on a 10 m course in 
primary care can therefore not be compared to that obtained 
on a longer course, eg, a 30 m course at the hospital. For 
researchers conducting multicentre trials, standardisation of 
the corridor length across centres is essential. The general 
thresholds of an absolute 6MWD or change in 6MWD for 
predicting mortality from the 6MWT do not apply for the 
6MWT on a 10 m course. A subsequent step in research 
should be the development of related 6MWT thresholds 
for predicting morbidity and mortality and a MCID for the 
6MWT on a 10 m course.
It is of great importance for clinicians and researchers 
to carefully consider the choice of reference equations in 
clinical tests. The difference of 49.5 m we identiﬁed shows 
the importance of choosing reference models established in 
accordance with the chosen course length. Using existing 
models to predict the 6MWD on a 10 m course revealed a 
signiﬁcant overestimation (with a range of 30–33% and an 
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Figure 1. Bland-Altman plot showing systematic lower 
performance on the six-minute walk test over a 10 
m-course in patients with COPD. 6MWD = six-minute 
walk distance. MCID = minimum clinically important 
disfference.
Figure 2. Bland-Altman plot showing the difference  
in %pred 6MWD using a 10 m versus 30 m course.  
%pred 6MWD is based on the average of predicted values 
from the studies of Gibbons et al (2001), Hill et al (2011), 
Jenkins et al (2009), and Troosters et al (1999).  
6MWD = six-minute walk distance.
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average of 8%pred lower compared to a 6MWT executed over 
30 m). This overestimation results in a worse representation 
of a COPD patient’s functional exercise capacity. Moreover, 
achieving a 6MWD of less than 82% of the predicted value 
can be considered abnormal (Troosters 1999), which may 
inﬂuence the patient’s treatment plan.
The test-retest reliability for the 6MWT based on the 10 
m course in the fairly homogeneous study population of 
people with COPD in this study was very high (ICC = 
0.98), which is consistent with previous studies (ICC = 
0.93) (Hernandes et al 2011). Future research is needed to 
study the validity and responsiveness for the 6MWT over 
a 10 m course. The order in which patients performed on 
the two test courses would not have affected the results of 
this study, due to the randomised double-crossover design 
and because, on average, patients walked about the same 
distances over the same course lengths. The non-signiﬁcant 
learning effect between the two tests on each course may 
have been due to the fact that patients in this study were 
familiar with the 6MWT. The learning effect of 0% and 
2% in this study cannot be compared to the results obtained 
by ﬁrst-time performers. Although this study shows a very 
low learning effect, it still falls within the range 0% to 17% 
described by the American Thoracic Society (2002).
A limitation of this study is that the signiﬁcant difference 
between 6MWDs on a 10 m course versus on a 30 m 
course was established for a small population of people 
with COPD. However, the demonstrated difference in walk 
distance of 49.5 m, and taking into account an alpha error 
level of 5%, reached statistical power of 89.9%. Considering 
the low prevalence of patients with COPD GOLD I in 
primary care practices, the distribution of people over the 
different GOLD stages in this study (Stage I 13%, Stage II 
47%, Stage III 27%, Stage IV 13%) is an adequate reﬂection 
of the distribution of COPD disease severity in primary 
care based on airway obstruction in a cross-sectional 
population-based study (Stage I 29%, Stage II 48%, Stage 
III 17%, Stage IV 5%) (Steuten et al 2006). The ﬁndings 
of this study are of particular relevance to practice in 
the Netherlands. However, there is clear relevance to all 
settings in which the 6MWT is conducted worldwide. The 
results of this study apply to individuals who walk 233 m 
or more on the 6MWT. In order to draw conclusions across 
different (patient) populations, Ng and colleagues showed 
a comparable signiﬁcant impact of different course lengths 
(10 m versus 30 m) on 6MWD in patients with stroke (41 
m) or healthy subjects (59 m) (Ng et al 2011, Ng et al 2013). 
The ﬁnding that course length has a substantial impact on 
the performance, and thus on the use of reference equations, 
may serve for a variety of chronic diseases like COPD, heart 
failure, rheumatoid arthritis, and neuromuscular disease.
In conclusion, our randomised double-crossover study in 45 
patients with COPD showed that course length (10 m versus 
30 m) substantially inﬂuences the performance of patients in 
a 6MWT. The statistical and clinically important difference 
in 6MWD in patients with COPD, singly depending on the 
length of the walk course, highlights a practical problem. 
Existing reference equations cannot be applied to predict 
the walking distance in the frequently used 6MWT on a 
10 m course for people with COPD, due to a substantial 
overestimation. Unique reference equations for the 6MWT 
on a 10 m course seem necessary. Q
Footnotes: aUA-767 Plus30, A&D Medical, Toshima Ku, 
Japan; bSpirobank and WinspiroPRO software, Gessate, 
Italy; cOnyx 9500, Nonin Medical Inc, Plymouth MN, USA.
Ethics: The institutional ethics committee of Maastricht 
University/Hospital approved the use of the 6MWT in 
this study, embedded in a cohort-nested randomised 
controlled trial. All participants received written and verbal 
information about the aim of the project and were required 
to give written informed consent prior to the screening.
Competing interests: The authors declare no conﬂict of 
interest related to this work.
Support: EB was funded by the Dutch Scientiﬁc College 
of Physiotherapy (WCF) of the Royal Dutch Society for 
Physical Therapy (KNGF), within the research program 
‘Designing Optimal Interventions in physical Therapy’ 
(DO-IT), a national co-operation of four Universities in The 
Netherlands.
Acknowledgements: The authors acknowledge the 
help of Melanie van der Veeke and her colleagues at 
the rehabilitation centre FysioMedica with recruiting 
participants and providing course space for testing. The 
authors are grateful to all participating patients. They also 
thank Walter Zeller for his contribution to the conception 
of the study and his help in developing the study protocol.
Correspondence: Dr Emmylou Beekman, Department of 
Epidemiology, Maastricht University, PO Box 616, 6200 
MD Maastricht, The Netherlands. Email: E.Beekman@
maastrichtuniversity.nl
References
Alameri H, Al-Majed S, Al-Howaikan A (2009) Six-min walk test 
in a healthy adult Arab population. Respiratory Medicine 
103: 1041–1046.
American Thoracic Society, Committee on Proﬁciency 
Standards for Clinical Pulmonary Function Laboratories 
(2002) ATS statement: Guidelines for the six-minute walk 
test. American Journal of Respiratory and Critical Care 
Medicine 166: 111–117.
Ben Saad H, Prefaut C, Tabka Z, Mtir AH, Chemit M, Hassaoune 
R, et al (2009) 6-minute walk distance in healthy North 
Africans older than 40 years: inﬂuence of parity. Respiratory 
Medicine 103: 74–84.
Brown CD, Wise RA (2007) Field tests of exercise in COPD: 
the six-minute walk test and the shuttle walk test. COPD 4: 
217–223.
Camarri B, Eastwood PR, Cecins NM, Thompson PJ, Jenkins 
S (2006) Six minute walk distance in healthy subjects aged 
55–75 years. Respiratory Medicine 100: 658–665.
Casanova C, Celli BR, Barria P, Casas A, Cote C, de Torres 
JP, et al (2011) The 6-min walk distance in healthy subjects: 
reference standards from seven countries. The European 
Respiratory Journal 37: 150–156.
Chetta A, Zanini A, Pisi G, Aiello M, Tzani P, Neri M, et al (2006) 
Reference values for the 6-min walk test in healthy subjects 
20–50 years old. Respiratory Medicine 100: 1573–1578.
Enright PL (2003) The six-minute walk test. Respiratory Care 
48: 783–785.
Enright PL, McBurnie MA, Bittner V, Tracy RP, McNamara R, 
Arnold A, et al (2003) The 6-min walk test: a quick measure 
of functional status in elderly adults. Chest 123: 387–398.
Journal of Physiotherapy 2013  Vol. 59  –  © Australian Physiotherapy Association 2013. Open access under CC BY-NC-ND license.
176
Research
Enright PL, Sherrill DL (1998) Reference equations for the 
six-minute walk in healthy adults. American Journal of 
Respiratory and Critical Care Medicine 158: 1384–1387.
Gibbons WJ, Fruchter N, Sloan S, Levy RD (2001) Reference 
values for a multiple repetition 6-minute walk test in healthy 
adults older than 20 years. Journal of Cardiopulmonary 
Rehabilitation and Prevention 21: 87–93.
Global Initiative for Chronic Obstructive Lung Disease (2010) 
Spirometry for health care providers. Available from: 
IUUQXXXHPMEDPQEPSHVQMPBETVTFSTG JMFT(0-%@
4QJSPNFUSZ@QEG
Gosselink RA, Langer D, Burtin C, Probst VS, Hendriks HJM, 
van der Schans CP, et al (2008) KNGF-Guideline for physical 
therapy in chronic obstructive pulmonary disease (Royal 
Dutch Society for Physical Therapy). Nederlands Tijdschrift 
voor Fysiotherapie   "WBJMBCMF GSPN IUUQTXXX
GZTJPOFUFWJEFODFCBTFEOMJNBHFTQEGTHVJEFMJOFT@JO@
FOHMJTIDPQE@QSBDUJDF@QSBDUJDF@HVJEFMJOFT@QEG
Hernandes NA, Wouters EF, Meijer K, Annegarn J, Pitta F, 
Spruit MA (2011) Reproducibility of 6-minute walking test in 
patients with COPD. The European Respiratory Journal 38: 
261–267.
Hill K, Wickerson LM, Woon LJ, Abady AH, Overend TJ, 
Goldstein RS, et al (2011) The 6-min walk test: responses in 
healthy Canadians aged 45 to 85 years. Applied Physiology, 
Nutrition, and Metabolism 36: 643–649.
Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, 
McDonald CF (2010) Updating the minimal important 
difference for six-minute walk distance in patients with 
chronic obstructive pulmonary disease. Archives of Physical 
Medicine and Rehabilitation 91: 221–225.
Iwama AM, Andrade GN, Shima P, Tanni SE, Godoy I, Dourado 
VZ (2009) The six-minute walk test and body weight-walk 
distance product in healthy Brazilian subjects. Brazilian 
Journal of Medical and Biological Research 42: 1080–1085.
Jenkins S, Cecins N, Camarri B, Williams C, Thompson 
P, Eastwood P (2009) Regression equations to predict 
6-minute walk distance in middle-aged and elderly adults. 
Physiotherapy Theory and Practice 25: 516–522.
Masmoudi K, Aouicha MS, Fki H, Dammak J, Zouari N (2008) 
The six minute walk test: which predictive values to apply 
for Tunisian subjects aged between 40 and 80 years? Tunis 
Med 86: 20–26.
Najaﬁ B, Helbostad JL, Moe-Nilssen R, Zijlstra W, Aminian K 
(2009) Does walking strategy in older people change as a 
function of walking distance? Gait Posture 29: 261–266.
Ng SS, Tsang WW, Cheung TH, Chung JS, To FP, Yu PC (2011) 
Walkway length, but not turning direction, determines the 
six-minute walk test distance in individuals with stroke. 
Archives of Physical Medicine and Rehabilitation 92: 806–
811.
Ng SS, Yu PC, To FP, Chung JS, Cheung TH (2013) Effect 
of walkway length and turning direction on the distance 
covered in the 6-minute walk test among adults over 50 
years of age: a cross-sectional study. Physiotherapy 99: 
63–70.
Osses AR, Yanez VJ, Barria PP, Palacios MS, Dreyse DJ, Diaz 
PO, et al (2010) Reference values for the 6-minutes walking 
test in healthy subjects 20–80 years old. Revista Medica de 
Chile 138: 1124–1130.
Pepera GK, Sandercock GR, Sloan R, Cleland JJ, Ingle L, 
Clark AL (2012) Inﬂuence of step length on 6-minute walk 
test performance in patients with chronic heart failure. 
Physiotherapy 98: 325–329.
Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR (2004) 
The 6-min walk distance: change over time and value 
as a predictor of survival in severe COPD. The European 
Respiratory Journal 23: 28–33.
Poh H, Eastwood PR, Cecins NM, Ho KT, Jenkins SC (2006) 
Six-minute walk distance in healthy Singaporean adults 
cannot be predicted using reference equations derived 
from Caucasian populations. Respirology 11: 211–216.
Polkey MI, Spruit MA, Edwards LD, Watkins ML, Pinto-Plata V, 
Vestbo J, et al (2013) Six minute walk test in COPD: minimal 
clinically important difference for death or hospitalization. 
American Journal of Respiratory and Critical Care Medicine 
187: 382–386.
Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, 
Schunemann HJ (2008) Interpretation of treatment changes 
in 6-minute walk distance in patients with COPD. The 
European Respiratory Journal 32: 637–643.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin 
R, Yernault JC (1993) Lung volumes and forced ventilatory 
ﬂows. Report Working Party Standardization of Lung 
Function Tests, European Community for Steel and Coal. 
Ofﬁcial Statement of the European Respiratory Society. The 
European Respiratory Journal 16: 5–40.
Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE 
(2009) The six-minute walk test: a useful metric for the 
cardiopulmonary patient. Internal Medicine Journal 39: 
495–501.
Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, 
et al (2003) Six-minute walk distance in chronic obstructive 
pulmonary disease: reproducibility and effect of walking 
course layout and length. American Journal of Respiratory 
and Critical Care Medicine 167: 1522–1527.
Soares MR, Pereira CA (2011) Six-minute walk test: reference 
values for healthy adults in Brazil. The Jornal Brasileiro de 
Pneumologia 37: 576–583.
Steuten LM, Creutzberg EC, Vrijhoef HJ, Wouters EF (2006) 
COPD as a multicomponent disease: inventory of dyspnoea, 
underweight, obesity and fat free mass depletion in primary 
care. The Primary Care Respiratory Journal 15: 84–91.
Troosters T, Gosselink R, Decramer M (1999) Six minute 
walking distance in healthy elderly subjects. The European 
Respiratory Journal 14: 270–274.
Tsang RCC (2005) Reference values for 6-minute walk test 
and hand-grip strength in healthy Hong Kong Chinese 
adults. Hong Kong Physiotherapy Journal 23: 6–11.
Yentes JM, Sayles H, Meza J, Mannino DM, Rennard SI, 
Stergiou N (2011) Walking abnormalities are associated 
with COPD: an investigation of the NHANES III dataset. 
Respiratory Medicine 105: 80–87.
Journal of Physiotherapy 2013  Vol. 59  –  © Australian Physiotherapy Association 2013. Open access under CC BY-NC-ND license.
